A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

BACKGROUND: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Crit Care
Glavni autori: Rello, Jordi, Krenn, Claus-Georg, Locker, Gottfried, Pilger, Ernst, Madl, Christian, Balica, Laura, Dugernier, Thierry, Laterre, Pierre-Francois, Spapen, Herbert, Depuydt, Pieter, Vincent, Jean-Louis, Bogár, Lajos, Szabó, Zsuzsanna, Völgyes, Barbara, Máñez, Rafael, Cakar, Nahit, Ramazanoglu, Atilla, Topeli, Arzu, Mastruzzo, Maria A., Jasovich, Abel, Remolif, Christian G., del Carmen Soria, Liliana, Andresen Hernandez, Max A., Ruiz Balart, Carolina, Krémer, Ildikó, Molnár, Zsolt, von Sonnenburg, Frank, Lyons, Arthur, Joannidis, Michael, Burgmann, Heinz, Welte, Tobias, Klingler, Anton, Hochreiter, Romana, Westritschnig, Kerstin
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291979/
https://ncbi.nlm.nih.gov/pubmed/28159015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13054-017-1601-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items